Outlook: Building the clinical data package
The potential combination of Cavatak (oncolytic virus) with checkpoint inhibitors represents a substantial commercial and partnering opportunity for Viralytics. The company is currently focused on building the clinical data package on Cavatak, which could prove attractive to big pharma companies seeking complementary therapies to boost immune responses to their checkpoint inhibitors. We see a potential deal for Cavatak in 2016 and value Viralytics at A$141m, or A$0.76 per share.Viralytics is engaged in advancing the clinical and preclinical development of its product CAVATAK™. Co. is actively progressing with development of CAVATAK across a range of cancers within targeted clinical trials.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.